NCT02982889 - Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

March 23, 2017

Study Completion Date

April 26, 2017

Conditions

Acute Pain

Interventions

DRUG

LIQ865A bupivacaine formulation

single subcutaneous injection in medial calf

DRUG

LIQ865B bupivacaine formulation

single subcutaneous injection in medial calf

DRUG

Diluent for LIQ865

Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection

DRUG

0.5% bupivacaine hydrochoride

single subcutaneous injection

Trial Locations (1)

2400

DanTrial Aps, Copenhagen